Cargando…

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackerman, Robert S., Muncey, Aaron R., Aldawoodi, Nasrin N., Kotha, Rohini, Getting, Rosemarie E. Garcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056594/
https://www.ncbi.nlm.nih.gov/pubmed/35141856
http://dx.doi.org/10.1007/s11912-022-01202-6
_version_ 1784697697551253504
author Ackerman, Robert S.
Muncey, Aaron R.
Aldawoodi, Nasrin N.
Kotha, Rohini
Getting, Rosemarie E. Garcia
author_facet Ackerman, Robert S.
Muncey, Aaron R.
Aldawoodi, Nasrin N.
Kotha, Rohini
Getting, Rosemarie E. Garcia
author_sort Ackerman, Robert S.
collection PubMed
description PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. SUMMARY: Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.
format Online
Article
Text
id pubmed-9056594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-90565942022-05-02 Cancer Immunotherapies: What the Perioperative Physician Needs to Know Ackerman, Robert S. Muncey, Aaron R. Aldawoodi, Nasrin N. Kotha, Rohini Getting, Rosemarie E. Garcia Curr Oncol Rep Anesthesiology and Critical Care (JP Cata, Section Editor) PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. SUMMARY: Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients. Springer US 2022-02-10 2022 /pmc/articles/PMC9056594/ /pubmed/35141856 http://dx.doi.org/10.1007/s11912-022-01202-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Anesthesiology and Critical Care (JP Cata, Section Editor)
Ackerman, Robert S.
Muncey, Aaron R.
Aldawoodi, Nasrin N.
Kotha, Rohini
Getting, Rosemarie E. Garcia
Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title_full Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title_fullStr Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title_full_unstemmed Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title_short Cancer Immunotherapies: What the Perioperative Physician Needs to Know
title_sort cancer immunotherapies: what the perioperative physician needs to know
topic Anesthesiology and Critical Care (JP Cata, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056594/
https://www.ncbi.nlm.nih.gov/pubmed/35141856
http://dx.doi.org/10.1007/s11912-022-01202-6
work_keys_str_mv AT ackermanroberts cancerimmunotherapieswhattheperioperativephysicianneedstoknow
AT munceyaaronr cancerimmunotherapieswhattheperioperativephysicianneedstoknow
AT aldawoodinasrinn cancerimmunotherapieswhattheperioperativephysicianneedstoknow
AT kotharohini cancerimmunotherapieswhattheperioperativephysicianneedstoknow
AT gettingrosemarieegarcia cancerimmunotherapieswhattheperioperativephysicianneedstoknow